Xtract Resources Plc (XTR) announced a fundraising today for £2,000,000 at a price of 0.60 pence per Ordinary Share principally for the ongoing advancement of its Silverking copper and Amghas antimony
Xtract Resources Plc (XTR) announced a fundraising today for £2,000,000 at a price of 0.60 pence per Ordinary Share principally for the ongoing advancement of its Silverking copper and Amghas antimony
The Telegraph: Rayner used disabled son’s NHS compensation to buy second home. The Deputy Prime Minister sold share of her Ashton-under-Lyne house to child’s trust for £162,500.
The Telegraph: Typical household energy bills will rise to £1,755 a year in October under the price cap. Ofgem, which sets the limit on what energy companies can charge customers, confirmed
Heathrow (apparently the Airport) announced its results for the 6 months ending June 30 2025. Robust H1 EBITDA – In the first six months of 2025, revenue grew 1.9% to £1,724
The Telegraph yesterday proved it does not have a clue regarding what it is doing on financial matters: Key moments from yesterday. The FTSE 100 is up 1% so far pre-market.
Metals One (MET1), which is advancing strategic minerals projects in Finland and Norway, is announced that the Company’s Råna Project partner and operator, Kingsrose Mining, has satisfied the conditions precedent to
Footsie closes down despite weekly gain. The FTSE 100 ended the week down 0.4%, though it gained 1.8% over the entire week. The leading gainer was the gambling company Entain, which
The FTSE 100 closed higher on Friday gaining an encouraging 1.2%. The top performer was NatWest, which rose by 7%, followed by Anglo American with a 5.1% increase.
Shield Therapeutics PLC (AIM: STX, OTCQX: SHIEF) shares surged 47% following the release of impressive second-quarter trading results.
Phoenix Copper (PXC), the AIM-quoted USA-focused base and precious metals company, announces that Paul de Gruchy has been appointed as Vice President of Investor Relations with immediate effect and will also
ECR Minerals (ECR), the exploration and development company focused on gold in Australia, announce the latest results for additional testing for the critical mineral Antimony (Sb) from diamond core previously drilled
Shield Therapeutics (STX), a commercial-stage pharmaceutical company, announced topline results for Q4 2023 and provides an unaudited trading update for the year ended 31 December 2023.